Built for better tomorrows: How Bridgeton delivers for patients

Kindeva’s Bridgeton facility offers a purpose-built solution for the complex and evolving landscape of injectable drugs. The facility was specifically designed to address challenges in sterile injectable manufacturing, such as the siloed approaches that often separate core functions like formulation and fill finish. By co-locating these functions and operating within integrated systems, the Bridgeton model helps to minimize risk, shorten timelines and improve overall process control.

This Q&A resource explains how the Bridgeton facility sets a new standard in sterile injectable manufacturing. It details the facility’s ability to maintain speed and sterility through isolator-based manufacturing and advanced process controls.
Bridgeton’s key features include:

• Integrated capabilities
  The site has dedicated formulation suites, quality control (QC) laboratories and final packaging capabilities, supporting a streamlined product flow and oversight throughout the entire production lifecycle.
• High-speed filling lines
  The facility features four high-speed filling lines from Groninger, Optima and Syntegon, each supporting a distinct container format: vials, cartridges or syringes.
• Advanced technology
  Bridgeton incorporates advanced process controls, including 100% in-process control and real-time statistical process control. Digital tools, such as electronic batch records and automated data capture, are also integrated throughout the operation.
• Flexibility
  The facility can support a wide range of therapies, including biologics, suspensions, controlled substances and high-potency formulations. It is also approved to handle Drug Enforcement Administration (DEA) Schedule III and IV controlled substances.

The Bridgeton model also reduces tech transfer risks by unifying all core manufacturing and testing capabilities within a single quality framework, which maintains traceability and alignment from early development through to commercial launch. This makes it a strong fit for complex injectable programs that require rapid scale-up and regulatory confidence.

Download our Q&A resource to discover how Kindeva’s Bridgeton facility helps answer the needs of both manufacturers and patients. 

To learn more about how Bridgeton sets a new standard in sterile injectable manufacturing, download the full eBook.